Diabeticcardiomyopathyreferstoacardiacdysfunctionobservedinpatientswithdiabetesthatoc- curs in absence of other cardiovascular disease, such as coronary artery disease, hypertension, valvular, and congenital heart disease. The main metabolic abnormalities promoting cardiac dysfunction are the resistance to the meta- bolic actions of insulin in heart tissue, compensatory hyperinsulinemia, and the progression of hyperglycemia. Two stages of diabetic cardiomyopathy are described: an early stage characterized by left ventric- ular hypertrophy and impaired diastolic function, and a late stage characterized by cardiac fibrosis and systolic dysfunction. The occurrence of HF in patients affected by DM significantly impacts on quality of life, manifesta- tion of new symptoms and worsening of existing symptoms, and on long-term prognosis. Notargettreatmentshavebeentestedindiabeticcardiomyopathy,thusclinicaltrialsareneededto define the role of available HF therapies or to find new therapeutic targets for this clinical condition.

Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications / Paolillo, S; Marsico, F; Prastaro, M; Renga, F; Esposito, L; De Martino, F; Di Napoli, P; Esposito, I; Ambrosio, A; Ianniruberto, M; Mennella, R; Paolillo, R. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - 15:3(2019), pp. 341-347. [10.1016/j.hfc.2019.02.003]

Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications.

Paolillo S
;
Marsico F;Prastaro M;Renga F;Esposito L;Di Napoli P;Esposito I;Ambrosio A;Ianniruberto M;
2019

Abstract

Diabeticcardiomyopathyreferstoacardiacdysfunctionobservedinpatientswithdiabetesthatoc- curs in absence of other cardiovascular disease, such as coronary artery disease, hypertension, valvular, and congenital heart disease. The main metabolic abnormalities promoting cardiac dysfunction are the resistance to the meta- bolic actions of insulin in heart tissue, compensatory hyperinsulinemia, and the progression of hyperglycemia. Two stages of diabetic cardiomyopathy are described: an early stage characterized by left ventric- ular hypertrophy and impaired diastolic function, and a late stage characterized by cardiac fibrosis and systolic dysfunction. The occurrence of HF in patients affected by DM significantly impacts on quality of life, manifesta- tion of new symptoms and worsening of existing symptoms, and on long-term prognosis. Notargettreatmentshavebeentestedindiabeticcardiomyopathy,thusclinicaltrialsareneededto define the role of available HF therapies or to find new therapeutic targets for this clinical condition.
2019
Diabetic Cardiomyopathy: Definition, Diagnosis, and Therapeutic Implications / Paolillo, S; Marsico, F; Prastaro, M; Renga, F; Esposito, L; De Martino, F; Di Napoli, P; Esposito, I; Ambrosio, A; Ianniruberto, M; Mennella, R; Paolillo, R. - In: HEART FAILURE CLINICS. - ISSN 1551-7136. - 15:3(2019), pp. 341-347. [10.1016/j.hfc.2019.02.003]
File in questo prodotto:
File Dimensione Formato  
heart failure clinics.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 327.03 kB
Formato Adobe PDF
327.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
heart failure clinics.pdf

solo utenti autorizzati

Licenza: Accesso privato/ristretto
Dimensione 327.03 kB
Formato Adobe PDF
327.03 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/812381
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 155
  • ???jsp.display-item.citation.isi??? 140
social impact